Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Legend Biotech ( (LEGN) ) has shared an announcement.
On June 6, 2025, Legend Biotech announced the availability of its updated corporate presentation, highlighting its achievements and strategic focus. The presentation underscores the company’s leadership in CAR-T therapy, particularly with its product CARVYKTI®, which has shown significant success in treating multiple myeloma. The company has experienced robust growth, with CARVYKTI® achieving industry-leading sales and a strong market presence. This development positions Legend Biotech as a transformative force in cancer care, with ongoing collaborations and a promising pipeline that could have significant implications for stakeholders and the broader industry.
The most recent analyst rating on (LEGN) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
Legend Biotech’s stock score is supported by strong sales growth and strategic developments highlighted in the earnings call, despite ongoing profitability challenges. Technical indicators and valuation concerns temper the overall outlook, though a robust cash position and positive future guidance provide optimism.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation is a prominent player in the biopharmaceutical industry, focusing on the development and commercialization of innovative cell therapies. The company is a leader in CAR-T therapy, with a strong emphasis on treating hematologic malignancies, solid tumors, and autoimmune diseases. Legend Biotech has a strategic partnership with Johnson & Johnson and Novartis, and it is known for its flagship product, CARVYKTI®, a CAR-T cell therapy for multiple myeloma.
Average Trading Volume: 1,566,807
Technical Sentiment Signal: Sell
Current Market Cap: $5.59B
Find detailed analytics on LEGN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue